Filing Details

Accession Number:
0001714899-24-000040
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-12 20:18:53
Reporting Period:
2024-01-10
Accepted Time:
2024-01-12 20:18:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1714899 Denali Therapeutics Inc. DNLI Biological Products, (No Disgnostic Substances) (2836) 463872213
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1724605 Carole Ho C/O Denali Therapeutics Inc.
161 Oyster Point Blvd.
South San Francisco CA 94080
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-01-10 4,668 $19.02 147,794 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 183,219 Indirect See footnote
Common Stock 25,000 Indirect See footnote
Footnotes
  1. The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29, 2023.
  2. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $18.61 to $19.57 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  3. Includes 136,904 RSUs.
  4. Reflects 15,558 shares previously disclosed as held indirectly; but have been determined to be held directly.
  5. The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
  6. The shares are held of record by The Rohatgi-Ho Irrevocable GST Trust for the benefit of the Reporting Person's children.